Crinetics Pharmaceuticals (CRNX) Stock Statistics & Valuation Metrics

Crinetics Pharmaceuticals has a market cap or net worth of $3.93B. The enterprise value is $3.85B.

Crinetics Pharmaceuticals has 104,705,330 shares outstanding. The number of shares has decreased by -2.65% in one year.

Crinetics Pharmaceuticals’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -48.89%.

The current PE Ratio of Crinetics Pharmaceuticals is ―. Crinetics Pharmaceuticals’s PEG ratio is -0.28.

In the last 12 months, Crinetics Pharmaceuticals had revenue of 7.70M and earned -465.32M in profits. Earnings per share was -4.95.

In the last 12 months, operating cash flow was -377.92M and capital expenditures -5.76M, giving a free cash flow of -383.68M billion.

Crinetics Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Crinetics Pharmaceuticals upcoming earnings date is May 7, 2026, TBA (Confirmed).

Crinetics Pharmaceuticals as a current ratio of 12.32, with Debt / Equity ratio of 4.89%

In the past 12 months, Crinetics Pharmaceuticals has paid 180.00K in taxes.

Crinetics Pharmaceuticals EV to EBITDA ratio is -9.38, with an EV/FCF ratio of -11.27.

Crinetics Pharmaceuticals has $1.03B in cash and marketable securities with $48.54M in debt, giving a net cash position of $979.35M billion.

Gross margin is 108.47%, with operating margin of -6714.77%, and net profit margin of -6046.22%.

The average price target for Crinetics Pharmaceuticals is $88.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy